Skip to main content
Equibles
ANNX logo

ANNX · Annexon, Inc.

Track ANNX — free

Use ANNX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANNX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.07 +0.07 (+1.79%)
Russell 2000 member Rebalance outlook locked
Market Cap
$817.78M
Shares
204.44M
Volume · Oct 9 301.7K Avg daily vol (3M) 3.11M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.00 Open$3.99 Day$3.86–4.04 52W close$2.68–6.96 Avg vol 30d3.2M Short int32.9M · 16.1% float · 11.7d Short vol46% Last earningsAug 12, 2026 DataJul 2020–Oct 2026 Filing10-Q · Aug 12

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$202.67M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-23.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$199.27M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+35.5%
Year over year · more shares
Price change (1Y)
+30.6%
Trailing year
Short interest
16.1%
Latest settlement · 11.7 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg −15%
below
RSI (14) 41
neutral
MACD trend Positive
52-week position 31%
mid-range
Momentum
relative strength
Very Weak
1-month return −3%
trailing
6-month return −39%
trailing
YTD return −20%
this year
Relative strength −48%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Distributing
2 of 217 funds reported for Sep 30 · net -463 sh shares
Insider flow Accumulating
Net +$99.8K over 90 days · 0% sells
Short interest Rising
16.08% of float · ▲ +2.4% MoM · 11.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
217 holders — near 3-yr high, broad support
Squeeze score 70
high risk · 0–100
Fundamentals
Poor
EPS growth −33%
Y/Y
Free cash flow $-186.5M
Quant / Vol
risk profile
Very High
Volatility 74%
annualized · 1-yr
Max drawdown −48%
past year
ATR 6.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
41 Neutral
MACD trend
Positive Bullish
52-week position
31% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Distributing
2 of 217 funds reported for Sep 30 · net -463 sh shares
Insider flow Accumulating
Net +$99.8K over 90 days · 0% sells
Short interest Rising
16.08% of float · ▲ +2.4% MoM · 11.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
217 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $4 · 31% Range high $7
vs 200-day avg -25% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ANNX
Annexon, Inc.
this stock
$817.78M -20.3% — — 16.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $127.55B +11.0% +46.2% 29.3 1.9%
MRNA
Moderna, Inc.
 $78.65B +568.0% +4.3% — 8.2%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.14B -4.2% +20.8% 18.3 2.5%
CSLLY
Csl Ltd
 $60.24B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
217
% held
87.9%
Reported
2 of 217
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
204
View
Short & Settlement
Short Interest Rising
Shares short
32.9M
Days to cover
11.7d
Change
+777.7K sh
View
Short Volume
Short vol %
46%
As of
Oct 8, 2026
Short Total
View
Fails to Deliver
FTD shares
4.7K
Value
$23.0K
As of
Sep 8, 2026
View
Off-Exchange
Off-exchange %
34.3%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$99.8K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-206.7M
EPS diluted
$-1.34
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 9, 2026
This year
18
View
Proposed Sales
Value
$10.6K
Shares
2.0K
Filed
Aug 13, 2026
View
Exempt Offerings
Offering
$130.5M
Filed
Jul 22, 2022
View
Earnings & Events
Webcasts
Last webcast
Sep 9, 2026
View

Performance

5D 20D 120D MTD YTD
ANNX -2.9% -3.4% -38.8% -5.4% -20.3%
SPY +1.3% +2.1% +9.0% +1.5% +13.5%
vs SPY -4.2% -5.5% -47.8% -6.9% -33.8%
Key facts CIK 1528115 CUSIP 03589W102 13F (30d) 4 filings 4 filers Visit website Investor relations